KPI Therapeutics
KPI Therapeutics is focused on developing potentially game changing autoimmune therapies. Our platform targets autoimmune diseases of the skin that have tens of millions of sufferers in the US and are a multi-billion-dollar market. Our lead drug, dalazatide, has completed Phase 1 trials and demonstrated clinical activity in patients.
KPI Therapeutics Offices
None Workspace
Typical time on-site:
None
Seattle, Washington, USA
